Welcome to this question-and-answer activity on key issues related to the targeted treatment of patients with severe uncontrolled asthma. Clinical pearls are provided to select among the 5 monoclonal antibodies currently approved for severe asthma in the United States based upon phenotype and other factors.
Want to learn more?
Visit Part 1 to learn answers to frequently asked questions on monoclonal antibody agents for severe asthma.
0.50 AANP Contact Hours
0.50 AMA PRA Category 1 CreditsTM
This activity is intended for allergists, pulmonologists, and other clinicians interested in the management of patients with severe uncontrolled asthma.
This activity is supported by an independent educational grant from GlaxoSmithKline.
Reynold A. Panettieri, Jr, MD
Vice Chancellor, Translational Medicine and Science
Director, Rutgers Institute for Translational Medicine and Science
Professor of Medicine, Rutgers University
New Brunswick, New Jersey
Emeritus Professor of Medicine, University of Pennsylvania